Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 9/20 | 0.52 |
| ▸ | GRIA2 | P42262 | 7/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9299052 | 1.00 | GRIK1 (0.52) | GRIK1GRIA2CYP1A2CYP2D6ALOX15 | |
| SCHEMBL3194382 | 1.00 | GRIK1 (0.52) | GRIK1GRIA2CYP1A2CYP2D6ALOX15 | |
| SCHEMBL12646596 | 1.00 | GRIK1 (0.52) | GRIK1GRIA2CYP1A2CYP2D6ALOX15 | |
| SCHEMBL12589787 | 1.00 | GRIK1 (0.52) | GRIK1GRIA2CYP1A2CYP2D6ALOX15 | |
| SCHEMBL9298943 | 0.86 | GRIK1 (0.52) | GRIK1GRIA2CYP1A2CYP2D6ALOX15 | |
| SCHEMBL642482 | 0.86 | GRIK1 (0.52) | GRIK1GRIA2CYP1A2CYP2D6ALOX15 | |
| SCHEMBL642481 | 0.86 | GRIK1 (0.52) | GRIK1GRIA2CYP1A2CYP2D6ALOX15 | |
| SCHEMBL7890460 | 0.86 | GRIK1 (0.52) | GRIK1GRIA2CYP1A2CYP2D6ALOX15 | |
| SCHEMBL9298944 | 0.86 | GRIK1 (0.52) | GRIK1GRIA2CYP1A2CYP2D6ALOX15 | |
| SCHEMBL7455717 | 0.86 | GRIK1 (0.52) | GRIK1GRIA2CYP1A2CYP2D6ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968733-B2 | Pyrrolidine analogue for preventing neurogenic pain and method for production thereof | GIFU UNIVERSITY (JP) | 2011-06-28 | — | — | US | disclosed |
| US-7968733-B2 | Pyrrolidine analogue for preventing neurogenic pain and method for production thereof | GIFU UNIVERSITY (JP) | 2011-06-28 | — | — | US | disclosed |
| US-20090306407-A1 | Pyrrolidine analogue for preventing neurogenic pain and method for production thereof | GIFU UNIVERSITY (JP) | 2009-12-10 | — | — | US | disclosed |
| US-20090306407-A1 | Pyrrolidine analogue for preventing neurogenic pain and method for production thereof | GIFU UNIVERSITY (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-0618810-A4 | BRADYKININ ANTAGONIST PEPTIDES. | SCIOS NOVA INC (US) | 1994-12-07 | — | — | EP | disclosed |
| EP-0618810-A1 | BRADYKININ ANTAGONIST PEPTIDES | SCIOS NOVA INC. (US) | 1994-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306407-A1 | Pyrrolidine analogue for preventing neurogenic pain and method for production thereof | HNMT, OPRK1, OPRL1 | GRIK1 672/4885GRIA2 1636/4885CYP1A2 3856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.